1.04
price up icon0.48%   0.005
after-market 시간 외 거래: 1.05 0.01 +0.96%
loading
전일 마감가:
$1.035
열려 있는:
$1.08
하루 거래량:
5.20M
Relative Volume:
1.17
시가총액:
$330.00M
수익:
-
순이익/손실:
$-63.08M
주가수익비율:
-3.8519
EPS:
-0.27
순현금흐름:
$-72.53M
1주 성능:
-4.59%
1개월 성능:
+11.73%
6개월 성능:
+44.81%
1년 성능:
-11.86%
1일 변동 폭
Value
$1.02
$1.09
1주일 범위
Value
$0.954
$1.15
52주 변동 폭
Value
$0.515
$1.979

오큐젠 Stock (OCGN) Company Profile

Name
명칭
Ocugen Inc
Name
전화
484-328-4701
Name
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
Name
직원
95
Name
트위터
@Ocugen
Name
다음 수익 날짜
2025-05-02
Name
최신 SEC 제출 서류
Name
OCGN's Discussions on Twitter

OCGN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
OCGN
Ocugen Inc
1.04 330.00M 0 -63.08M -72.53M -0.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.82 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
520.29 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.94 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.53 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
267.12 28.51B 3.81B -644.79M -669.77M -6.24

오큐젠 Stock (OCGN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-10-15 개시 Maxim Group Buy
2023-03-01 업그레이드 Chardan Capital Markets Neutral → Buy
2022-08-23 개시 Mizuho Buy
2022-06-15 재개 ROTH Capital Buy
2022-06-02 개시 Cantor Fitzgerald Overweight
2021-07-26 개시 Noble Capital Markets Outperform
2021-06-11 다운그레이드 ROTH Capital Buy → Neutral
2021-05-07 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2021-02-09 다운그레이드 Chardan Capital Markets Buy → Neutral
2021-02-04 업그레이드 H.C. Wainwright Neutral → Buy
모두보기

오큐젠 주식(OCGN)의 최신 뉴스

pulisher
Jun 18, 2025

Ocugen: Three Potential Gene-Therapy Filings By 2028 (NASDAQ:OCGN) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 17, 2025

FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Ocugen to Release New Investor Presentation - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Ocugen gets FDA clearance to begin mid-stage study of OCU410ST - MSN

Jun 17, 2025
pulisher
Jun 16, 2025

OCGN Gains as FDA Approves Trial for Stargardt Disease Therapy - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial - Benzinga

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen gets FDA nod to begin mid-stage study of OCU410ST (OCGN) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen’s IND amendment to begin phase 2/3 confirmatory trial of OCU410ST cleared by FDA - Ophthalmology Times

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease - Ocugen

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen Gets FDA Clearance to Start Phase 2/3 Stargardt Disease Trial - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen (OCGN) Receives FDA Clearance for Key Gene Therapy Trial - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

FDA clears Ocugen’s phase 2/3 trial for Stargardt disease therapy - Investing.com

Jun 16, 2025
pulisher
Jun 13, 2025

Ocugen to Showcase Gene Therapy Advancements at 2025 BIO International Convention - MSN

Jun 13, 2025
pulisher
Jun 11, 2025

Ocugen To Present at BIO International Convention 2025 | OCGN St - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Ocugen To Present at BIO International Convention 2025 - Ocugen

Jun 11, 2025
pulisher
Jun 11, 2025

Ocugen To Present at BIO International Convention 2025 | OCGN Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Ocugen, Inc. to Present at 2025 BIO International Convention, Showcasing Gene Therapy Advancements for Blindness Diseases - Nasdaq

Jun 11, 2025
pulisher
Jun 11, 2025

Ocugen Showcases Breakthrough Blindness Gene Therapy Platform at BIO 2025 After Korean Partnership Deal - Stock Titan

Jun 11, 2025
pulisher
Jun 10, 2025

Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy - MSN

Jun 10, 2025
pulisher
Jun 09, 2025

Ocugen Secures Licensing Agreement for OCU400 in Korea - MSN

Jun 09, 2025
pulisher
Jun 08, 2025

Ocugen signs license deal with Korean company for gene therapy - MSN

Jun 08, 2025
pulisher
Jun 08, 2025

Ocugen, Inc. (NASDAQ:OCGN) Position Boosted by Wellington Management Group LLP - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Ameriprise Financial Inc. Invests $30,000 in Ocugen, Inc. (NASDAQ:OCGN) - Defense World

Jun 08, 2025
pulisher
Jun 05, 2025

Ocugen Signs License Agreement for OCU400 in Korea - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen signs term sheet for korean licensing of OCU400 gene therapy - Ophthalmology Times

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen stock rises on Korean licensing deal for gene therapy By Investing.com - Investing.com Nigeria

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen stock rises on Korean licensing deal for gene therapy - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen stock gains on licensing deal (OCGN:NASDAQ) - Seeking Alpha

Jun 05, 2025
pulisher
Jun 05, 2025

BNP Paribas Financial Markets Acquires Shares of 36,859 Ocugen, Inc. (NASDAQ:OCGN) - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of Ocu400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen inks $11 million gene therapy deal for Korean market - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - Ocugen

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen Signs Deal for Korean Rights to Gene Therapy OCU400 - marketscreener.com

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen inks $11 million gene therapy deal for Korean market By Investing.com - Investing.com Canada

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen announcing signing of term sheet, enter licensing agreement for OCU400 - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing Of Binding Term Sheet For The License Of Ocu400 Modifier Gene Therapy For Retinitis Pigmentosa In Korea - marketscreener.com

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the Lic - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea | OCGN Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen's Blindness Gene Therapy Lands Major Korean Deal: $11M Upfront, 25% Royalties - Stock Titan

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene ... - Bluefield Daily Telegraph

Jun 05, 2025
pulisher
Jun 05, 2025

OCGNOcugen Provides Business Update with First Quarter 2025 Financial Results - Revista ADVFN

Jun 05, 2025
pulisher
Jun 04, 2025

Ocugen, Inc. (NASDAQ:OCGN) Stock Position Raised by ProShare Advisors LLC - Defense World

Jun 04, 2025
pulisher
Jun 02, 2025

Malvern-Based Ocugen to Pursue Rare Pediatric Disease Therapy - VISTA.Today

Jun 02, 2025
pulisher
Jun 01, 2025

Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN

Jun 01, 2025
pulisher
May 31, 2025

Ocugen Receives Rare Pediatric Disease Designation for OCU410ST - MSN

May 31, 2025
pulisher
May 29, 2025

FDA awards Ocugen drug with Rare Pediatric Disease Designation - Pennsylvania Business Report -

May 29, 2025
pulisher
May 28, 2025

Ocugen’s Gene Therapy OCU410ST Nets Rare Pediatric Disease Designation for ABCA4-Associated Retinopathies - CGTLive®

May 28, 2025
pulisher
May 28, 2025

Ocugen wins FDA rare pediatric disease status for genetic eye disorder treatment - MSN

May 28, 2025

오큐젠 (OCGN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

오큐젠 주식 (OCGN) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Fernandes Prabhavathi
Director
Nov 26 '24
Buy
0.91
10,000
9,095
10,000
Castillo Kirsten
Director
Nov 22 '24
Buy
0.91
25,000
22,848
75,000
$20.52
price down icon 1.06%
$35.91
price down icon 0.64%
$21.27
price up icon 1.67%
$104.85
price down icon 0.99%
$104.80
price down icon 0.28%
biotechnology ONC
$267.12
price up icon 0.12%
자본화:     |  볼륨(24시간):